NO CHANGES IN BLOOD PRESSURE IN DIALYSIS PATIENTS AFTER 12 MONTHS OF TREATMENT WITH IV/SC CERA (CONTINUOUS ERYTHROPOIETIN RECEPTOR ACTIVATOR)

被引：0
|
作者：
Dougherty, Frank C.
Beyer, Ulrich
机构：
来源：
NEPHROLOGY | 2005年 / 10卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：A313 / A314
页数：2
相关论文
共 50 条
  • [1] Effect of a continuous erythropoietin receptor activator (CERA) on stable haemoglobin in patients with CKD on dialysis: once monthly administration
    Locatelli, Francesco
    Villa, Giuseppe
    de Francisco, Angel L. M.
    Albertazzi, Alberto
    Adrogue, Horacio J.
    Dougherty, Frank C.
    Beyer, Ulrich
    [J]. CURRENT MEDICAL RESEARCH AND OPINION, 2007, 23 (05) : 969 - 979
  • [2] Comparison of dose requirement, serum erythropoietin and blood pressure following intravenous and subcutaneous erythropoietin treatment of dialysis patients - IV and SC erythropoietin
    Jensen, JD
    Madsen, JK
    Jensen, LW
    [J]. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1996, 50 (03) : 171 - 177
  • [3] Subcutaneous (SC) CERA (continuous erythropoietin receptor activator) administered once every 2 weeks effectively corrects anemia in patients with chronic kidney disease (CKD) on dialysis and not on dialysis
    Provenzano, R
    Dougherty, FC
    [J]. AMERICAN JOURNAL OF KIDNEY DISEASES, 2006, 47 (04) : A50 - A50
  • [4] Pharmacokinetic (PK) and pharmacodynamic (PD) profiles of intravenous (IV) administrations of CERA (continuous erythropoietin receptor activator) in chronic kidney disease (CKD) patients not on dialysis
    Tsubakihara, Yoshiharu
    Bessho, Masami
    Suzuki, Masashi
    [J]. NEPHROLOGY DIALYSIS TRANSPLANTATION, 2006, 21 : 150 - 150
  • [5] Nanomedicines in the treatment of anemia in renal disease: focus on CERA (Continuous Erythropoietin Receptor Activator)
    Panchapakesan, Usha
    Sumual, Siska
    Pollock, Carol
    [J]. INTERNATIONAL JOURNAL OF NANOMEDICINE, 2007, 2 (01): : 33 - 38
  • [6] ANALYSIS OF FACTORS ASSOCIATED WITH THE DOSE OF CONTINUOUS ERYTHROPOIETIN RECEPTOR ACTIVATOR (CERA) IN PD PATIENTS
    Yasuhiro, Suzuki
    Masashi, Mizuno
    Humiko, Sakata
    Hiroshi, Kinashi
    Shoichi, Maruyama
    Seiichi, Matsuo
    Yasuhiko, Ito
    [J]. NEPHROLOGY, 2014, 19 : 111 - 111
  • [7] Efficacy & safety of continuous erythropoietin receptor activator (CERA) in treating renal anaemia in diabetic patients with chronic kidney disease not on dialysis
    Vankar, Sameer G.
    Dutta, Pinaki
    Kohli, H. S.
    Bhansali, Anil
    [J]. INDIAN JOURNAL OF MEDICAL RESEARCH, 2014, 139 : 112 - 116
  • [8] SAFETY AND TOLERABILITY PROFILE OF CONTINUOUS ERYTHROPOIETIN RECEPTOR ACTIVATOR (CERA) WITH EXTENDED DOSING INTERVALS IN PATIENTS WITH CHRONIC KIDNEY DISEASE ON DIALYSIS
    Dougherty, Frank C.
    Beyer, Ulrich
    [J]. NEPHROLOGY, 2005, 10 : A313 - A313
  • [9] Subcutaneous CERA (Continuous Erythropoietin Receptor Activator) maintains hemoglobin concentrations with dosing intervals up to 4 weeks in dialysis patients
    Locatelli, F
    Villa, G
    Beyer, U
    Dougherty, FC
    [J]. NEPHROLOGY DIALYSIS TRANSPLANTATION, 2005, 20 : V261 - V261
  • [10] Influence of continuous erythropoietin receptor activator (CERA) administration intervals on erythropoietic effect in hemodialysis patients
    Daimon S.
    Nuka H.
    Kitada K.
    Suzuki Y.
    Kim F.
    Kawano M.
    [J]. Renal Replacement Therapy, 2 (1)
12345